66
Participants
Start Date
August 31, 2004
Primary Completion Date
March 31, 2011
Study Completion Date
March 31, 2011
Tarceva
Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status
Temodar
Temodar 200 mg/m\^2/day x 5 days every 28 days
Radiation Therapy
Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
UCSF Department of Neurological Surgery, San Francisco
Collaborators (1)
Genentech, Inc.
INDUSTRY
University of California, San Francisco
OTHER